Wednesday, October 7, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleCrunchbase News

The Rising Investors Behind The New Unicorn Class

View original at news.crunchbase.com
Crunchbase News - Funding Ma Title: The Rising Investors Behind The New Unicorn Class Date: 2026-03-17 11:00 Source: https://news.crunchbase.com/venture/unicorn-investment-momentum-ai-sequoia-a16z-2025/ <p>The race to back the next generation of billion-dollar startups accelerated last year as the stable of unicorn sta…
Opening lines of the source · Crunchbase News · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Cutting-edge companies in today's market risk being taken over by AI developments which erode their advantage and wipe away their lead

    60% confidence

  • The pace of new unicorn creation picked up each quarter in 2025 and has shown no signs of slowing in 2026

    60% confidence

  • Nearly half of the new unicorns are very young: 94 of them are less than 5 years old

    60% confidence

  • 187 companies joined The Crunchbase Unicorn Board in 2025, up 61% from the previous year, driven largely by the AI boom

    60% confidence

  • AI-native companies accounted for 47 of last year's new unicorns, or 25% of the total

    60% confidence

  • Investors who want to back the next market winners need to keep investing

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com